8-K filed May 16, 2024, 7:59 PM ET ticker NORD CIK 0001011060

M&A confidence high sentiment positive materiality 0.90

Nordicus acquires 95% of Orocidin A/S for $38M in stock, enters periodontitis market

Nordicus Partners Corp

Acquired 525,597 Orocidin shares (95% stake) from 11 shareholders for 38M restricted common shares.
Consideration valued at $38M in an all-stock transaction; closed May 13, 2024.
Nordicus CEO Henrik Rouf and Director Henrik Keller join Orocidin's board of directors.
Orocidin is a clinical-stage biopharma developing QR-01 for periodontitis; global market estimated >$1.3B by 2029.

item 1.01 item 2.01 item 3.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-24-020152
form_type: 8-K
ticker: NORD
cik: 0001011060
company_name: Nordicus Partners Corp
filed_at: 2024-05-16T23:59:59+00:00
discovered_at: 2026-05-14T18:03:16.863565+00:00
generated_at: 2026-06-01T18:26:36.948993+00:00
sec_items: ["1.01", "2.01", "3.02", "9.01"]
event_type: m_and_a
sentiment: positive
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-24-020152
json_url: https://secwatch.observer/filing/0001493152-24-020152.json
markdown_url: https://secwatch.observer/filing/0001493152-24-020152.md
text_url: https://secwatch.observer/filing/0001493152-24-020152.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

a791b2497fa5694819f95d7ed249234ccb058e82

Nordicus Partners Corp completed an acquisition involving certain shareholders of Orocidin A/S (closed 2024-05-13).

the Company acquired the Orocidin Shares pursuant to the Agreement.

SEC 8-K Item 2.01/5.01 confidence 0.9 SEC evidence

3bae1550a36d41a793cc417d9a5674836ee45605

Nordicus Partners Corp entered into Stock Purchase and Sale Agreement with certain shareholders of Orocidin A/S (effective 2024-05-13).

On May 13, 2024, Nordicus Partners Corporation (the “Company”) and certain shareholders (the “Sellers”) of Orocidin A/S, a Danish stock corporation (“Orocidin”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock.

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

KLXE

KLX Energy acquires Wolfpack assets for $17M; also exchanges $2.19M notes for equity

KLX Energy Services Holdings, Inc. June 2, 2026, 5:14 PM ET m_and_a Items 1.01, 2.01, 3.02, 7.01, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 3.02, 9.01 same event type: m_and_a similar materiality

This filing

the Company acquired the Orocidin Shares pursuant to the Agreement.

Comparable filing

“Buyer”), the Company and, solely for purposes of Section 8.05 thereto, Stevie Cooper and Stewart Cooper (the “Purchase Agreement”). The purchase price for the Acquisition is $17.0 million, subject to customary post-closing adjustments and to be paid as follows: (i) on the Closing Date, the Buyer paid the Seller $14.0 million in cash; (ii) 180 days after the

Filing page SEC filing

XRN

Chiron Real Estate closes $249M acquisition of two senior housing communities; issues $100M Series C preferred

Chiron Real Estate Inc. June 2, 2026, 4:30 PM ET m_and_a Items 1.01, 2.01, 2.03, 3.02, 3.03, 5.03, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 3.02, 9.01 same event type: m_and_a similar materiality

This filing

the Company acquired the Orocidin Shares pursuant to the Agreement.

Comparable filing

On June 1, 2026, the Company, through one or more subsidiaries, closed on the acquisition of The Landing Alexandria (the “ Landing ”), a senior housing community located in Alexandria, Virginia for a purchase price of $130 million.

Filing page SEC filing

WLY

Wiley acquires Emerald Publishing for $452M; adds ~500 journals, expected accretive in year one

JOHN WILEY & SONS, INC. June 2, 2026, 8:30 AM ET m_and_a Items 1.01, 2.01, 7.01, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 9.01 same event type: m_and_a similar materiality

This filing

the Company acquired the Orocidin Shares pursuant to the Agreement.

Comparable filing

pursuant to which Buyer acquired from the Seller all of the issued and outstanding equity securities of Emerald Holding (the "Transaction") in exchange for GBP £337.5 million (approximately $452 million)

Filing page SEC filing

OCFC

OceanFirst closes acquisition of Flushing Financial; issues shares to Warburg Pincus

OCEANFIRST FINANCIAL CORP June 1, 2026, 5:19 PM ET m_and_a Items 1.01, 3.02, 2.01, 2.03, 3.03, 5.02, 5.03, 7.01, 9.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 3.02, 9.01 same event type: m_and_a similar materiality

This filing

the Company acquired the Orocidin Shares pursuant to the Agreement.

Comparable filing

of Flushing (“ Flushing Common Stock ”) issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was converted into the right to receive 0.85 of a share (the “ Exchange Ratio ”) of common stock, par value $0.01 per share, of OceanFirst (“ OceanFirst Common Stock ” and such consideration, the “ Merger Consideration ”).

Filing page SEC filing

RPAY

REPAY closes $372M acquisition of KUBRA, funded with new $500M term loan

Repay Holdings Corp June 1, 2026, 4:14 PM ET m_and_a Items 1.01, 2.01, 1.02, 9.01, 2.03, 7.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 9.01 same event type: m_and_a similar materiality

This filing

the Company acquired the Orocidin Shares pursuant to the Agreement.

Comparable filing

KUBRA became an indirect wholly owned subsidiary of the Company. Pursuant to the Purchase Agreement, the aggregate cash purchase price for the Acquisition was approximately $372 million, subject to customary post-closing adjustments. The closing cash consideration was funded with a combination of cash on hand and borrowings under the Credit Agreement described

Filing page SEC filing

OLOX

Olenox acquires CS Digital for $30M upfront; launches gas-powered data center platform

OLENOX INDUSTRIES INC. May 28, 2026, 8:30 AM ET m_and_a Items 1.01, 5.03, 2.01, 2.03, 3.02, 7.01, 8.01, 9.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 3.02, 9.01 same event type: m_and_a similar materiality

This filing

the Company acquired the Orocidin Shares pursuant to the Agreement.

Comparable filing

of CS Digital (the “Acquisition”) on the same date. Aggregate Consideration. The aggregate consideration payable by the Company under the Purchase Agreement consists of: (i) US$30,000,000 in upfront consideration, payable at closing, comprised of (a) US$14,000,000 in newly issued shares of the Company’s Series D Preferred Stock, par value $1.00 per share (the

Filing page SEC filing

HYEX

Healthy Extracts Inc. acquires Adli Gummies Inc. for notes and equity

HEALTHY EXTRACTS INC. May 18, 2026, 3:25 PM ET m_and_a Items 1.01, 2.01, 3.02, 5.02, 9.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 3.02, 9.01 same event type: m_and_a similar materiality

This filing

the Company acquired the Orocidin Shares pursuant to the Agreement.

Comparable filing

On May 15, 2026, we entered into an Acquisition Agreement (the “Acquisition Agreement”) with Adli Gummies Inc., an Ontario corporation which does business as Imaraïs Beauty (“Adli”), and its shareholders. Pursuant to the Acquisition Agreement, through our wholly-owned subsidiary Healthy Extracts Canada Inc., a British Columbia corporation (“HE Canada”), we acquired one-hundred percent (100%) of the outstanding membership interests of Adli, which became our wholly-owned subsidiary.

Filing page SEC filing

QNCX

Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts

Quince Therapeutics, Inc. May 18, 2026, 9:33 AM ET m_and_a Items 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 3.02, 9.01 same event type: m_and_a similar materiality

This filing

the Company acquired the Orocidin Shares pursuant to the Agreement.

Comparable filing

On May 18, 2026, the Company completed its acquisition of the Orphai Entities.

Filing page SEC filing

Source: SEC EDGAR

accession 0001493152-24-020152

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.